The funding agreement will offset program costs for Teva, which will lead the clinical development of the schizophrenia treatment and regulatory process and is responsible for commercialization.
In preliminary third quarter results, Magic Software Systems says third quarter revenue will be $129.3 million; previous guidance was $142.4-143.1 million.